Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period

References

• Van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp Pharmacol. 2011;205:51–75.
   PubMedGoogle Scholar
• Samardzic J, Allegaert K, Bajcetic M. Developmental pharmacology: a moving target. Int J Pharm. 2015;492:335–337.
   PubMed Web of Science ®Google Scholar
• Williams K, Thomson D, Seto I, et al. Standard 6: age groups for pediatric trials. Pediatrics. 2012;129:S153–60.
   PubMed Web of Science ®Google Scholar
• Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proceed. 2011;86:156–167.
   PubMed Web of Science ®Google Scholar
• Yaffe SJ, Aranda JV. Neonatal and pediatric pharmacology: therapeutic principles in practice. 4th ed. Philadelphia (PA): Lippincott Williams Wilkins; 2011.
   Google Scholar
• Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375:1969–1987.
   PubMed Web of Science ®Google Scholar
• Kaufman D, Fairchild KD. Clinical microbiology ofbacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17:638–680.
   PubMed Web of Science ®Google Scholar
• Ohlin A, Björkman L, Serenius F, et al. Sepsis as a risk factor for neonatal morbidity in extremely preterm infants. Acta Paediatr. 2015. doi:10.1111/apa.13104.
   Web of Science ®Google Scholar
• Remington JS, Klein JO, Wilson CB, et al. Infectious diseases of the fetus and newborn infant. 7th. Philadelphia (PA): Elsevier Saunders; 2011.
   Google Scholar
• Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report from the national institute of child health and human development neonatal research network. J Pediatr. 1996;129:63–71.
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Hansen NI, Sanchez PJ, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. early onset sepsis: the Burden of Group B streptococcal and E. Coli disease continues. Pediatrics. 2011;127:817–826.
   PubMed Web of Science ®Google Scholar
• van den Anker JN. How to optimize the evaluation and use of antibiotics in neonates. Early Hum Dev. 2014;90:S10–2.
   PubMed Web of Science ®Google Scholar
• MacDonald MG, Mullett MD, Seshia MMK. Avery’s neonatology: pathophysiology & management of the newborn. 6th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
   Google Scholar
• Sherwin CM, Medlicott NJ, Reith DM, et al. Intravenous drug delivery in neonates: lessons learnt. Arch Dis Child. 2014;99:590–594.
   PubMed Web of Science ®Google Scholar
• Allegaert K, Anderson BJ, Vrancken M, et al. Impact of a paediatric vial on the magnitude of systematic medication errors in neonates. Paediatr Perinat Drug Ther. 2006;7:59–63.
   Google Scholar
• Samardzic J, Turner MA, Bax R, et al. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol. 2015;11:1041–1052.
   PubMed Web of Science ®Google Scholar
• Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99–110.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52:1–8.
   PubMed Web of Science ®Google Scholar
• Zeitlinger MA, Sauermann R, Traunmüller F, et al. Impact of plasma protein binding on antimicrobial activity using time-killing curves. J Antimicrob Chemother. 2004;54:876–880.
   PubMed Web of Science ®Google Scholar
• Smits A, Kulo A, Verbesselt R, et al. Cefazolin plasma protein binding and its covariates in neonates. Eur J Clin Microbiol Infect Dis. 2012;31:3359–3365.
   PubMed Web of Science ®Google Scholar
• Pullen J, Stolk LM, Degraeuwe PL, et al. Protein binding of flucloxacillin in neonates. Ther Drug Monit. 2007;29:279–283.
   PubMed Web of Science ®Google Scholar
• Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm. 2013;452:3–7.
   PubMed Web of Science ®Google Scholar
• Ahsman MJ, Wildschut ED, Tibboel D, et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2010;54:1734–1741.
   PubMed Web of Science ®Google Scholar
• Schreuder MF, Bueters RR, Allegaert K. The interplay between drugs and the kidney in premature neonates. Pediatr Nephrol. 2014;29:2083–2091.
   PubMed Web of Science ®Google Scholar
• Vieux R, Hascoet JM, Merdariu D, et al. Glomerular filtration rate reference values in very preterm infants. Pediatrics. 2010;125:e1186–92.
   PubMed Web of Science ®Google Scholar
• De Cock RF, Allegaert K, Sherwin CM, et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res. 2014;31:754–767.
   PubMed Web of Science ®Google Scholar
• De Cock RF, Allegaert K, Brussee JM, et al. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res. 2014;31:2643–2654.
   PubMed Web of Science ®Google Scholar
• Rhodin MM, Anderson BJ, Peters AM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24:67–76.
   PubMed Web of Science ®Google Scholar
• De Cock RF, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51:105–117.
   PubMed Web of Science ®Google Scholar
• Bueters RR, Kusters LJ, Klaasen A, et al. Antibiotics and renal branching morphogenesis: comparison of toxicities. Pediatr Res. 2014;76:508–514.
   PubMed Web of Science ®Google Scholar
• Girardi A, Raschi E, Galletti S, et al. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf. 2015;38:535–551.
   PubMed Web of Science ®Google Scholar
• Yaffe SJ, Aranda JV, Van Den Anker JN. Neonatal and pediatric pharmacology: therapeutic principles in practice. 3rd ed. Philadelphia: Lippincott Williams Wilkins; 2005.
   Google Scholar
• Chen N, Aleksa K, Woodland C, et al. Ontogeny of drug elimination by the human kidney. Pediatr Nephrol. 2006;21:160–168.
   PubMed Web of Science ®Google Scholar
• Engle WA. American Academy of Pediatrics Committee on Fetus and Newborn. Age Terminology during the Perinatal Period. Pediatrics. 2004;114:1362–1364.
   PubMed Web of Science ®Google Scholar
• Rodieux F, Wilbaux M, van den Anker JN, et al. Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet. 2015;54:1183–1204.
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259–263.
   PubMed Web of Science ®Google Scholar
• Kandasamy Y, Smith R, Wright IM. Measuring cystatin C to determine renal function in neonates. Pediatr Crit Care Med. 2013;14:318–322.
   PubMed Web of Science ®Google Scholar
• Brou NA, Jacqz-Aigrain E, Zhao W. Cystatin C as a potential biomarker for dosing of renally excreted drugs. Br J Clin Pharmacol. 2015;80:20–27.
   PubMed Web of Science ®Google Scholar
• Pfister M, D’Argenio DZ. The emerging scientific discipline of pharmacometrics. J Clin Pharmacol. 2010;50:6S.
   PubMed Web of Science ®Google Scholar
• De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67:5–16.
   PubMed Web of Science ®Google Scholar
• van der Graaf PH. CPT: pharmacometrics and systems pharmacology. CPT Pharmacomet Syst Pharmacol. 2012;1:e8.
   PubMedGoogle Scholar
• Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacomet Syst Pharmacol. 2013;2:e38.
   PubMedGoogle Scholar
• Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2011;21:291–301.
   PubMed Web of Science ®Google Scholar
• Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacomet Syst Pharmacol. 2013;2:e63.
   PubMedGoogle Scholar
• Sheiner LB. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab Rev. 1984;15:153–171.
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Lane JR, Romanowski GL, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41:927–934.
   PubMed Web of Science ®Google Scholar
• Allegaert K, Anderson BJ, Van Den Anker JN, et al. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29:284–291.
   PubMed Web of Science ®Google Scholar
• Smith PB, Cohen-Wolkowiez M, Castro LM, et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J. 2011;30:844–849.
   PubMed Web of Science ®Google Scholar
• Van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother. 2009;53:3871–3879.
   PubMed Web of Science ®Google Scholar
• Fuchs A, Guidi M, Giannoni E, et al. Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. Br J Clin Pharmacol. 2014;78:1090–1101.
   PubMed Web of Science ®Google Scholar
• Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther. 1988;43:565–570.
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18–55.
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E, Zhao W, Sharland M, et al. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med. 2013;18:28–34.
   PubMed Web of Science ®Google Scholar
• Vandendriessche A, Allegaert K, Cossey V, et al. Prospective validation of neonatal vancomycin dosing regimens is urgently needed. Curr Ther Res Clin Exp. 2014;76:51–57.
   PubMedGoogle Scholar
• Jacqz-Aigrain E, Leroux S, Zhao W, et al. How to use vancomycin optimally in neonates: remaining questions. Expert Rev Clin Pharmacol. 2015;8:635–648.
   PubMed Web of Science ®Google Scholar
• Bhongsatiern JJ, Stockmann C, Yu T, et al. Renal function descriptors in neonates: which creatinine-based formula best describes vancomycin clearance? J Clin Pharmacol. 2015. doi:10.1002/jcph.650.
   PubMedGoogle Scholar
• Kimura T, Sunakawa K, Matsuura N, et al. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48:1159–1167.
   PubMed Web of Science ®Google Scholar
• Mehrotra N, Tang L, Phelps SJ, et al. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations. Pharmacotherapy. 2012;32:408–419.
   PubMed Web of Science ®Google Scholar
• Zhao W, Lopez E, Biran V, et al. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98:449–453.
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Hersh AL, El-Komy MH, et al. Association between vancomycin trough concentration and area under the concentration-time curve in neonates. Antimicrob Agents Chemother. 2014;58:6454–6461.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45:755–773.
   PubMed Web of Science ®Google Scholar
• Mulla H. Understanding developmental pharmacodynamics: importance for drug development and clinical practice. Paediatr Drugs. 2010;12:223–233.
   PubMedGoogle Scholar
• Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011;128:e1242–9.
   PubMed Web of Science ®Google Scholar
• Kent A, Turner MA, Sharland M, et al. Aminoglycoside toxicity in neonates: something to worry about ? Expert Rev Anti Infect Ther. 2014;12:319–331.
   PubMed Web of Science ®Google Scholar
• Standing JF, Tuleu C. Paediatric formulations–Getting to the heart of the problem. Int J Pharm. 2005;300:56–66.
   PubMed Web of Science ®Google Scholar
• de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol. 2011;7:935–948.
   PubMed Web of Science ®Google Scholar
• de Lange DW. Glomerular hyperfiltration of antibiotics. Neth J Crit Care. 2013;17:10–14.
   Google Scholar
• de Cock P, Standing J, Barker C, et al. Augmented renal clearance implies a need for increased amoxicillin-clavulanate dosing in critically ill children. Arch Dis Child. 2016;101:e1.
   PubMedGoogle Scholar
• Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012;16:R113.
   PubMed Web of Science ®Google Scholar
• Tröger U, Drust A, Martens-Lobenhoffer J, et al. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int J Antimicrob Agents. 2012;40:370–372.
   PubMed Web of Science ®Google Scholar
• Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest. 2012;142:30–39.
   PubMed Web of Science ®Google Scholar
• Prowle JR, Molan MP, Hornsey E, et al. Measurement of renal blood flow by phase-contrast magnetic resonance imaging during septic acute kidney injury: a pilot investigation. Crit Care Med. 2012;40:1768–1776.
   PubMed Web of Science ®Google Scholar
• van den Anker JN, Allegaert K. Pharmacokinetics of aminoglycosides in the newborn. Curr Pharm Des. 2012;18:3114–3118.
   PubMed Web of Science ®Google Scholar
• Kadambari S, Heath PT, Sharland M, et al. Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units. J Antimicrob Chemother. 2011;66:2647–2650.
   PubMed Web of Science ®Google Scholar
• De Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43:417–440.
   PubMed Web of Science ®Google Scholar
• Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol. 2013;75:1068–1080.
   PubMed Web of Science ®Google Scholar
• Samardzic J, Smits A, Cossey V, et al. To what extent does the vancomycin assay contribute to the variability in vancomycin concentration estimates in neonates? Arch Dis Child. 2016;101:e1.
   PubMedGoogle Scholar
• Allegaert K, van den Anker JN, Creatinine-based vancomycin dosing regimens in neonates: there is more to consider than the variation in drug assay. Pharmacotherapy. 2012;32:e174. discussion e175.
   PubMed Web of Science ®Google Scholar
• Allegaert K, van den Anker JN. Adverse drug reactions in neonates and infants: a population-tailored approach is needed. Br J Clin Pharmacol. 2015;80:788–795.
   PubMed Web of Science ®Google Scholar
• Metsvaht T, Nellis G, Varendi H, et al. High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination. BMC Pediatr. 2015;15:41.
   PubMed Web of Science ®Google Scholar
• Smits A, De Cock RF, Allegaert K, et al. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59:6344–6351.
   PubMed Web of Science ®Google Scholar
• Ramos-Martín V, Johnson A, Livermore J, et al. Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates. J Antimicrob Chemother. 2016. doi:10.1093/jac/dkv451.
   PubMedGoogle Scholar